DVT & pulmonary embolism (PE). Prevention of VTE in adults who have undergone elective hip or knee replacement surgery; recurrent DVT & PE. Reduce risk of stroke, systemic embolism, & death in patients w/ non-valvular atrial fibrillation w/ ≥1 risk factors, including patients unsuitable for warfarin.
AdultDVT & PE 10 mg bid for 7 days, followed by 5 mg bid. Prevention of VTE (elective hip or knee replacement surgery) 2.5 mg bid. Administer initial dose at least 12-24 hr after surgery. Recommended duration of treatment: Patient undergoing hip replacement surgery 32-38 days, knee replacement surgery 10-14 days. Prevention of recurrent DVT & PE 2.5 mg bid after at least 6 mth of treatment for DVT or PE. Prevention of stroke & systemic embolism (non-valvular atrial fibrillation) 5 mg bid. Elderly ≥80 yr, either weighing ≤60 kg or w/ serum creatinine ≥1.5 mg/dL Reduce dose to 2.5 mg bid.
Discontinue use in patients w/ active pathological hemorrhage. Temporarily interrupt use prior to any elective surgery or other invasive procedure to reduce risk of bleeding. Increased risk & can cause serious, potentially fatal bleeding; thrombotic events in premature discontinuation of any oral anticoagulant. Signs & symptoms of blood loss. Not recommended in severe hepatic & renal impairment. Patients undergoing dialysis. Pregnancy. Not recommended during lactation.
Sign Out
